Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Mantle-Cell 1

Interventions

Rituximab 41Cyclophosphamide 23Peripheral Blood Stem Cell Transplantation 15Lenalidomide 14ibrutinib 11fludarabine phosphate 11Etoposide 10Bortezomib 10Filgrastim 9Bendamustine Hydrochloride 9Mycophenolic Acid 8Melphalan 8Cytarabine 8venetoclax 7fludarabine 7Whole-Body Irradiation 7Vincristine 7Cyclosporine 7CT-P10 7Methotrexate 6obinutuzumab 5acalabrutinib 5Doxorubicin 5Carmustine 5Carboplatin 5Biopsy 5pembrolizumab 4ibritumomab tiuxetan 4carmustine, poliferprosan 20 drug combination 4Tacrolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Mantle-Cell × loncastuximab tesirine × Clear all
NCT03684694 2024-02-06

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

ADC Therapeutics S.A.

Phase 1/2 Terminated
136 enrolled 33 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡